Vol 27, No 5 (2020)
Research letters — Clinical cardiology
Published online: 2020-08-07

open access

Page views 831
Article views/downloads 825
Get Citation

Connect on Social Media

Connect on Social Media

First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases

Ewa Dziewięcka1, Mateusz Winiarczyk2, Matylda Gliniak2, Monika Kaciczak2, Sylwia Wiśniowska-Śmiałek1, Aleksandra Karabinowska1, Katarzyna Holcman1, Magdalena Kostkiewicz1, Marta Hlawaty1, Agata Leśniak-Sobelga1, Piotr Podolec1, Paweł Rubiś1
Pubmed: 32789840
Cardiol J 2020;27(5):639-641.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Lenzen M, Ryden L, Ohrvik J, et al. Euro Heart Survey Investigators. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006; 27(24): 2969–2974.
  2. Gasior M, Pres D, Stasik-Pres G, et al. Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. Cardiol J. 2008; 15(5): 422–430.
  3. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
  4. Kralev S, Krause B, Papavassiliu T, et al. Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors. Cardiol J. 2009; 16(3): 234–240.
  5. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
  6. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(19): 1880–1882.
  7. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19): 1526–1534.
  8. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382(10): 972–973.
  9. Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015; 314(1): 52–60.
  10. Sharma A, Zhao X, Hammill B, et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure. Circ Hear Fail. 2018; 11(6).